Sinnige, Jante S.
Filippini, Daan F. L.
Hagens, Laura A.
Heijnen, Nanon F. L.
Schnabel, Ronny M.
Schultz, Marcus J.
Bergmans, Dennis C. J. J.
Bos, Lieuwe D. J.
Smit, Marry R.
Article History
Received: 19 April 2024
Accepted: 26 June 2024
First Online: 8 July 2024
Declarations
:
: Ethical approval for the protocol was obtained from the ethics committee of the Amsterdam UMC (ref: W18_311 #18.358) and from the MUMC + (ref: 2019–1137). All included patients or legal representatives provided deferred consent for the use of data.
: Not applicable.
: LB declares that he have received a grant from Health Holland (10.2.17.181PPS) via the Dutch Lung Foundation for the submitted work. The grant provider had no role in the study design, data collection, analysis, and interpretation of the results. Outside of the submitted work, LB declares receiving grants from the Longfonds, Innovative Medicine Initiative, Amsterdam UMC, Health Holland, ZonMW, Volition, and Santhera. Furthermore, LB has contributed to advisory boards for Sobi NL, Impentri, Novartis, AstraZeneca, CSL Behring, and has received consulting fees from Scailyte.